Market Overview

Cancer Genetics Sharply Higher After Interpace Buys Biopharma Unit

Share:
Cancer Genetics Sharply Higher After Interpace Buys Biopharma Unit

Cancer Genetics (NASDAQ: CGIX) shares are trading sharply higher after Interpace Diagnostics (NASDAQ: IDXG) said it purchased the Biopharma Services unit of the Cancer Genetics.

Interpace Diagnostics shares are also trading higher after Ampersand Capital Partners agreed to invest $27 million in the company in two tranches of newly issued convertible preferred stock.

Cancer Genetics shares are up 53% at 27 cents in Tuesday’s pre-market session. The stock has a 52-week high of $1.30 and a 52-week low of 15 cents per share.

Interpace Diagnostics shares are up 3.8% at 72 cents in Tuesday’s pre-market session. The stock has a 52-week high of $1.78 and a 52-week low of 67 cents per share.

Related Links:

JPMorgan Q2 Earnings Beat Estimates

Johnson & Johnson Trades Higher On Q2 Earnings Beat

Posted-In: News Penny Stocks Health Care Asset Sales Markets General Best of Benzinga

 

Related Articles (CGIX + IDXG)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Khiron Life Sciences To Participate At Cosmoprof North America

Domino's Pizza Falls After Posting Mixed Q2 Earnings, Weak Sales